{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T16:36:04Z","timestamp":1784306164139,"version":"3.55.0"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seizure-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seizure: European Journal of Epilepsy"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.seizure.2025.10.001","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T02:23:41Z","timestamp":1760063021000},"page":"114-127","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Efficacy and safety of cannabidiol in children with developmental and epileptic encephalopathies: A systematic review"],"prefix":"10.1016","volume":"133","author":[{"given":"Anna","family":"Saranti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinelopi","family":"Dragoumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Pavlogiannis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelos","family":"Pavlou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Zafeiriou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.seizure.2025.10.001_bib0001","doi-asserted-by":"crossref","unstructured":"R.K. Manokaran, S. Sharma, and R. Ramachandrannair, \u201cThe 2022 International League Against Epilepsy Classification and Definition of childhood Epilepsy syndromes : an update for pediatricians,\u201d 2024.","DOI":"10.1007\/s13312-024-3115-2"},{"key":"10.1016\/j.seizure.2025.10.001_bib0002","doi-asserted-by":"crossref","unstructured":"S.M. Zuberi et al., \u201cILAE classification and definition of epilepsy syndromes with onset in neonates and infants : position statement by the ILAE Task Force on nosology and definitions,\u201d no. April 2021, pp. 1349\u201397, 2022, doi: 10.1111\/epi.17239.","DOI":"10.1111\/epi.17239"},{"key":"10.1016\/j.seizure.2025.10.001_bib0003","doi-asserted-by":"crossref","unstructured":"N. Specchio et al., \u201cInternational League Against Epilepsy classification and definition of epilepsy syndromes with onset in childhood : position paper by the ILAE Task Force on nosology and Definitions,\u201d no. April 2021, pp. 1398\u2013442, 2022, doi: 10.1111\/epi.17241.","DOI":"10.1111\/epi.17241"},{"key":"10.1016\/j.seizure.2025.10.001_bib0004","doi-asserted-by":"crossref","unstructured":"I.E. Scheffer et al., \u201cILAE POSITION PAPER ILAE classification of the epilepsies : position paper of the ILAE Commission for Classification and Terminology,\u201d pp. 512\u201321, 2017, doi: 10.1111\/epi.13709.","DOI":"10.1111\/epi.13709"},{"key":"10.1016\/j.seizure.2025.10.001_bib0005","article-title":"Developmental and e \u00ad pi \u00ad le \u00ad ptic e \u00ad nc \u00ad ep \u00ad ha \u00ad lo \u00ad pa \u00ad thies","volume":"0123456789","author":"Scheffer","year":"2024","journal-title":"Nat Rev Dis Prim"},{"issue":"8","key":"10.1016\/j.seizure.2025.10.001_bib0006","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1093\/brain\/awz195","article-title":"Incidence and phenotypes of childhood-onset genetic epilepsies: a prospective population-based national cohort","volume":"142","author":"Symonds","year":"2019","journal-title":"Brain"},{"key":"10.1016\/j.seizure.2025.10.001_bib0007","article-title":"Infantile spasms: etiology, lead time and treatment response in a resource limited setting","volume":"14","author":"Surana","year":"2020","journal-title":"Epilepsy Behav reports"},{"issue":"5","key":"10.1016\/j.seizure.2025.10.001_bib0008","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/cge.14481","article-title":"The clinical and genetic landscape of developmental and epileptic encephalopathies in Egyptian children","volume":"105","author":"Elkhateeb","year":"2024","journal-title":"Clin Genet"},{"issue":"4","key":"10.1016\/j.seizure.2025.10.001_bib0009","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1111\/dmcn.15433","article-title":"Epileptic spasms: a South African overview of aetiologies, interventions, and outcomes","volume":"65","author":"Raga","year":"2023","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.seizure.2025.10.001_bib0010","doi-asserted-by":"crossref","unstructured":"G. Poke, J. Stanley, I.E. Scheffer, and L.G. Sadleir, \u201cEpidemiology of developmental and epileptic encephalopathy and of intellectual disability and epilepsy in children,\u201d 2023, doi: 10.1212\/WNL.0000000000206758.","DOI":"10.1212\/WNL.0000000000206758"},{"issue":"2","key":"10.1016\/j.seizure.2025.10.001_bib0011","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/j.1528-1167.2011.03358.x","article-title":"Unifying the definitions of sudden unexpected death in epilepsy","volume":"53","author":"Nashef","year":"2012","journal-title":"Epilepsia"},{"issue":"4","key":"10.1016\/j.seizure.2025.10.001_bib0012","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2016-1933","article-title":"Fatal cerebral edema with status epilepticus in children with dravet syndrome: report of 5 cases","volume":"139","author":"Myers","year":"2017","journal-title":"Pediatrics"},{"issue":"16","key":"10.1016\/j.seizure.2025.10.001_bib0013","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000207080","article-title":"Rates of status epilepticus and sudden unexplained death in epilepsy in people with genetic developmental and epileptic encephalopathies","volume":"100","author":"Donnan","year":"2023","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.seizure.2025.10.001_bib0014","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1111\/epi.16849","article-title":"The role of new medical treatments for the management of developmental and epileptic encephalopathies: novel concepts and results","volume":"62","author":"Landmark","year":"2021","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2025.10.001_bib0015","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.yebeh.2016.11.033","article-title":"Historical perspective on the medical use of cannabis for epilepsy: ancient times to the 1980s","volume":"70","author":"Friedman","year":"2017","journal-title":"Epilepsy Behav"},{"issue":"2","key":"10.1016\/j.seizure.2025.10.001_bib0016","doi-asserted-by":"crossref","first-page":"61","DOI":"10.14581\/jer.17012","article-title":"Cannabinoids in the treatment of epilepsy: hard evidence at last?","volume":"7","author":"Perucca","year":"2017","journal-title":"J epilepsy Res"},{"issue":"4","key":"10.1016\/j.seizure.2025.10.001_bib0017","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s13311-015-0377-3","article-title":"Molecular targets of cannabidiol in neurological disorders","volume":"12","author":"Bih","year":"2015","journal-title":"Neurotherapeutics"},{"issue":"13","key":"10.1016\/j.seizure.2025.10.001_bib0018","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1007\/s40265-019-01171-4","article-title":"Pharmacological and therapeutic properties of cannabidiol for epilepsy","volume":"79","author":"Franco","year":"2019","journal-title":"Drugs"},{"issue":"13","key":"10.1016\/j.seizure.2025.10.001_bib0019","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26136234","article-title":"Dysregulation of the cannabinoid system in childhood epilepsy: from mechanisms to therapy","volume":"26","author":"Montebello","year":"2025","journal-title":"Int J Mol Sci"},{"issue":"10","key":"10.1016\/j.seizure.2025.10.001_bib0020","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1007\/s40263-018-0558-9","article-title":"Efficacy and safety of adjunctive cannabidiol in patients with Lennox-Gastaut Syndrome: a systematic review and meta-analysis","volume":"32","author":"Lattanzi","year":"2018","journal-title":"CNS Drugs"},{"issue":"3","key":"10.1016\/j.seizure.2025.10.001_bib0021","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s40263-020-00708-6","article-title":"Adjunctive cannabidiol in patients with Dravet Syndrome: a systematic review and meta-analysis of efficacy and safety","volume":"34","author":"Lattanzi","year":"2020","journal-title":"CNS Drugs"},{"key":"10.1016\/j.seizure.2025.10.001_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2022.114238","article-title":"Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: a systematic review and meta-analysis","volume":"359","author":"Talwar","year":"2023","journal-title":"Exp Neurol"},{"issue":"2","key":"10.1016\/j.seizure.2025.10.001_bib0023","doi-asserted-by":"crossref","first-page":"203","DOI":"10.25259\/JNRP_618_2023","article-title":"Use of cannabidiol in the treatment of drug-refractory epilepsy in children and young adults: a systematic review","volume":"15","author":"Chico","year":"2024","journal-title":"J Neurosci Rural Pract"},{"key":"10.1016\/j.seizure.2025.10.001_bib0024","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.seizure.2025.10.001_bib0025","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jclinepi.2016.01.021","article-title":"PRESS Peer Review of electronic search strategies: 2015 guideline statement","volume":"75","author":"McGowan","year":"2016","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.seizure.2025.10.001_bib0026","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.seizure.2025.10.001_bib0027","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.seizure.2025.10.001_bib0028","unstructured":"\u201cRisk of bias In non-randomized studies \u2013 of interventions, version 2 (ROBINS-I V2).\u201d https:\/\/sites.google.com\/site\/riskofbiastool\/welcome\/robins-i-v2."},{"key":"10.1016\/j.seizure.2025.10.001_bib0029","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1056\/NEJMoa1611618","article-title":"Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome","volume":"376","author":"Devinsky","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.seizure.2025.10.001_bib0030","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1001\/jamaneurol.2020.0073","article-title":"Dose-ranging effect of adjunctive oral cannabidiol vs placebo on convulsive seizure frequency in dravet syndrome","volume":"77","author":"Miller","year":"2020","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.seizure.2025.10.001_bib0031","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.yebeh.2018.05.013","article-title":"Open-label use of highly purified CBD (Epidiolex\u00ae) in patients with CDKL5 deficiency disorder and Aicardi, Dup15q, and Doose syndromes","volume":"86","author":"Devinsky","year":"2018","journal-title":"Epilepsy Behav"},{"issue":"4","key":"10.1016\/j.seizure.2025.10.001_bib0032","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s40272-019-00341-x","article-title":"Purified cannabidiol for treatment of refractory epilepsies in pediatric patients with developmental and epileptic encephalopathy","volume":"21","author":"Pietrafusa","year":"2019","journal-title":"Paediatr Drugs"},{"issue":"1","key":"10.1016\/j.seizure.2025.10.001_bib0033","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s40263-018-0589-2","article-title":"Long-term safety, tolerability, and efficacy of cannabidiol in children with refractory epilepsy: results from an expanded access program in the US","volume":"33","author":"Sands","year":"2019","journal-title":"CNS Drugs"},{"issue":"50","key":"10.1016\/j.seizure.2025.10.001_bib0034","doi-asserted-by":"crossref","first-page":"e427","DOI":"10.3346\/jkms.2020.35.e427","article-title":"Cannabidiol for treating Lennox-Gastaut syndrome and Dravet Syndrome in Korea","volume":"35","author":"Koo","year":"2020","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.seizure.2025.10.001_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2019.106826","article-title":"Synthetic pharmaceutical grade cannabidiol for treatment of refractory infantile spasms: a multicenter phase-2 study","volume":"102","author":"Hussain","year":"2020","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.seizure.2025.10.001_bib0036","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ejpn.2019.12.024","article-title":"Response to cannabidiol in epilepsy of infancy with migrating focal seizures associated with KCNT1 mutations: an open-label, prospective, interventional study","volume":"25","author":"Poisson","year":"2020","journal-title":"Eur J Paediatr Neurol"},{"issue":"August","key":"10.1016\/j.seizure.2025.10.001_bib0037","first-page":"1","article-title":"Slow titration of cannabidiol add-on in drug-resistant epilepsies can improve safety with maintained efficacy in an open-label study","volume":"11","author":"D\u2019Onofrio","year":"2020","journal-title":"Front Neurol"},{"issue":"9","key":"10.1016\/j.seizure.2025.10.001_bib0038","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.23930","article-title":"Safety and tolerability of transdermal cannabidiol gel in children with developmental and epileptic encephalopathies: a nonrandomized controlled trial","volume":"4","author":"Scheffer","year":"2021","journal-title":"JAMA Netw open"},{"key":"10.1016\/j.seizure.2025.10.001_bib0039","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2023.109245","article-title":"Cannabidiol in children with treatment-resistant epilepsy with myoclonic-atonic seizures","volume":"143","author":"Caraballo","year":"2023","journal-title":"Epilepsy Behav"},{"issue":"April","key":"10.1016\/j.seizure.2025.10.001_bib0040","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.seizure.2023.05.003","article-title":"Retrospective chart review study of use of cannabidiol (CBD) independent of concomitant clobazam use in patients with Lennox-Gastaut syndrome or Dravet syndrome","volume":"110","author":"Nabbout","year":"2023","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2025.10.001_bib0041","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.seizure.2024.01.010","article-title":"Purified cannabidiol as add-on therapy in children with treatment-resistant infantile epileptic spasms syndrome","volume":"115","author":"Reyes Valenzuela","year":"2024","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2025.10.001_bib0042","article-title":"The use of cannabidiol in patients with Lennox-Gastaut syndrome and Dravet syndrome in the UK Early Access Program: a retrospective chart review study","volume":"29","author":"Eltze","year":"2025","journal-title":"Epilepsy Behav reports"},{"key":"10.1016\/j.seizure.2025.10.001_bib0043","unstructured":"\u201cCritical appraisal Skills Programme (2018). CASP Cohort Studies checklist\u201d."},{"key":"10.1016\/j.seizure.2025.10.001_bib0044","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(18)30136-3","article-title":"Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"391","author":"Thiele","year":"2018","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.seizure.2025.10.001_bib0045","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/S1474-4422(15)00379-8","article-title":"Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial","volume":"15","author":"Devinsky","year":"2016","journal-title":"lancet Neurol"},{"key":"10.1016\/j.seizure.2025.10.001_bib0046","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2023.109159","article-title":"Real-world, long-term evaluation of the tolerability and therapy retention of Epidiolex\u00ae (cannabidiol) in patients with refractory epilepsy","volume":"141","author":"Georgieva","year":"2023","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.seizure.2025.10.001_bib0047","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2022.108958","article-title":"Outcomes from a Spanish Expanded Access Program on cannabidiol treatment in pediatric and adult patients with epilepsy","volume":"137","author":"Villanueva","year":"2022","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.seizure.2025.10.001_bib0048","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2020.106988","article-title":"Cannabidiol in treatment of refractory epileptic spasms: an open-label study","volume":"106","author":"Herlopian","year":"2020","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.seizure.2025.10.001_bib0049","unstructured":"\u201cPhase 3 trial of cannabidiol (CBD; GWP42003-P) for infantile spasms: open-label extension Phase (GWPCARE7)\u201d."},{"issue":"15","key":"10.1016\/j.seizure.2025.10.001_bib0051","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1212\/WNL.0b013e318232de76","article-title":"Randomized, phase III study results of clobazam in Lennox-Gastaut syndrome","volume":"77","author":"Ng","year":"2011","journal-title":"Neurology"},{"issue":"21","key":"10.1016\/j.seizure.2025.10.001_bib0052","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1212\/01.wnl.0000303813.95800.0d","article-title":"Rufinamide for generalized seizures associated with Lennox\u2013Gastaut syndrome","volume":"70","author":"Glauser","year":"2008","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.seizure.2025.10.001_bib0053","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s40272-016-0171-7","article-title":"Pharmacotherapy for Dravet Syndrome","volume":"18","author":"Wallace","year":"2016","journal-title":"Pediatr Drugs"},{"issue":"8","key":"10.1016\/j.seizure.2025.10.001_bib0054","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1111\/epi.14477","article-title":"Long-term safety and treatment effects of cannabidiol in children and adults with treatment-resistant epilepsies: expanded access program results","volume":"59","author":"Szaflarski","year":"2018","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2025.10.001_bib0055","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.eplepsyres.2019.03.015","article-title":"Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: expanded access program results","volume":"154","author":"Laux","year":"2019","journal-title":"Epilepsy Res"},{"issue":"17","key":"10.1016\/j.seizure.2025.10.001_bib0056","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1007\/s40265-018-0992-5","article-title":"Efficacy and safety of cannabidiol in epilepsy: a systematic review and meta-analysis","volume":"78","author":"Lattanzi","year":"2018","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.seizure.2025.10.001_bib0057","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s40263-021-00807-y","article-title":"Highly purified cannabidiol for epilepsy treatment: a systematic review of epileptic conditions beyond Dravet syndrome and Lennox-Gastaut Syndrome","volume":"35","author":"Lattanzi","year":"2021","journal-title":"CNS drugs"},{"key":"10.1016\/j.seizure.2025.10.001_bib0058","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-072348","article-title":"Balancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomised controlled trials and observational studies","volume":"382","author":"Solmi","year":"2023","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.seizure.2025.10.001_bib0059","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1358\/dot.2019.55.3.2909248","article-title":"Cannabidiol as adjunctive treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome","volume":"55","author":"Lattanzi","year":"2019","journal-title":"Drugs Today (Barc)"},{"issue":"6","key":"10.1016\/j.seizure.2025.10.001_bib0060","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1111\/epi.16546","article-title":"Cannabidiol efficacy and clobazam status: a systematic review and meta-analysis","volume":"61","author":"Lattanzi","year":"2020","journal-title":"Epilepsia"},{"issue":"8","key":"10.1016\/j.seizure.2025.10.001_bib0061","doi-asserted-by":"crossref","first-page":"e85","DOI":"10.1111\/epi.16596","article-title":"Thrombocytopenia in pediatric patients on concurrent cannabidiol and valproic acid","volume":"61","author":"McNamara","year":"2020","journal-title":"Epilepsia"},{"issue":"5","key":"10.1016\/j.seizure.2025.10.001_bib0062","doi-asserted-by":"crossref","first-page":"547","DOI":"10.3988\/jcn.2022.18.5.547","article-title":"Effects of cannabidiol on adaptive behavior and quality of life in pediatric patients with treatment-resistant epilepsy","volume":"18","author":"Kim","year":"2022","journal-title":"J Clin Neurol"},{"issue":"8","key":"10.1016\/j.seizure.2025.10.001_bib0063","doi-asserted-by":"crossref","first-page":"e96","DOI":"10.1111\/epi.13815","article-title":"Quality of life in childhood epilepsy in pediatric patients enrolled in a prospective, open-label clinical study with cannabidiol","volume":"58","author":"Rosenberg","year":"2017","journal-title":"Epilepsia"},{"issue":"2","key":"10.1016\/j.seizure.2025.10.001_bib0064","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1528-1167.2010.02915.x","article-title":"Factors determining response to antiepileptic drugs in randomized controlled trials. A systematic review and meta-analysis","volume":"52","author":"Rheims","year":"2011","journal-title":"Epilepsia"}],"container-title":["Seizure: European Journal of Epilepsy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131125002699?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131125002699?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,7]],"date-time":"2025-12-07T08:08:11Z","timestamp":1765094891000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1059131125002699"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":63,"alternative-id":["S1059131125002699"],"URL":"https:\/\/doi.org\/10.1016\/j.seizure.2025.10.001","relation":{},"ISSN":["1059-1311"],"issn-type":[{"value":"1059-1311","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of cannabidiol in children with developmental and epileptic encephalopathies: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Seizure: European Journal of Epilepsy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seizure.2025.10.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 British Epilepsy Association. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}